Downstream Bioprocessing: More is More
What's good for upstream processes -- higher concentration levels for MAbs and proteins -- can strain downstream operations, forcing manufacturers to rethink the purification train.
A process development specialist
at Protherics, Inc. works with a
GE Chromaflow column.By Angelo De Palma, Ph.D., Contributing Editor
The dramatic rise in volumetric productivity for cell culture-based manufacturing has been a mixed blessing for bioprocessors. Although desirable from a cost of goods perspective, protein concentrations in the gram-plus per liter range stress the capabilities of processes designed for much lower titers.
“High expression levels for MAbs and fusion proteins have taxed purification processes,” says Dr. Brian D. Kelley, director of purification process development at Wyeth Biopharma (Andover, Mass.).
Fermentation and cell culture operations occupy approximately the same floor space in a traditional biomanufacturing facility. Tenfold increases in protein titers, which biotech has enjoyed over the past 10 to 15 years, strains the downstream material flow capacity. “What seems like a good thing for the upstream process actually creates new challenges for the downstream process because we’re now handling much more material within the same square footage,” observes Kelley.
One consequence has been the need to stage purification of the process stream through multiple cycles for many unit operations, which requires that product be sufficiently stable in the in-process pools being held for the next cycle of operation. Another effect is the need to work at much higher volumes. “In the past it wasn’t unusual to see a hundredfold concentration after capture,” Kelley notes. With protein titers routinely reaching the two to four gram per liter range, concentration factors of ten are more common.
Chromatography resins with high protein binding capacities have helped minimize column sizes and in-process pool volumes. Newer resins that bind or capture 50 to 80 milligrams per liter of sorbent have replaced media with binding capacities in the 10 to 30 mg/mL range. Newer resins also tend to be manufactured from less-compressible materials, which withstand high pressures from higher flow rates. These resins (see "Downstream Synergies" sidebar) may be packed to higher bed heights and cleaned more aggressively than some polymer-based sorbents.
“Older, more compressible resins didn’t serve large volume processes very well,” says Kelley. “Resin vendors realized that and stepped up to give us many more options.” He adds that current process chromatography equipment and resins should keep up with the increased titers for a few years more, until the titers exceed ten grams per liter.
Initial cell removal and clarification steps are also burdened by the elevated cell densities and extended culture times commonly employed to raise protein titers. Processors have therefore migrated from filtration toward continuous centrifugation for initial clarification of mammalian cell cultures. Centrifugation was originally thought to be too harsh for mammalian cells, but this is not the case for newer centrifuges with carefully designed inlet distributors.
Centrifugation produces feedstreams that require more polishing compared to streams subjected to microfiltration, which increases the need for high-capacity depth filters downstream of the clarification step. “There’s been a steady evolution and competition among major filtration vendors over the last five years, but cleaning up harvest feedstreams still represents a challenge because of our high debris load which needs to be removed to protect chromatography columns,” says Kelley.
Cell culture’s high productivity has caused a shift in the cost of goods equation from fermentation to purification. Wyeth Biopharma has responded with initiatives on process intensification, yield maximization, and minimizing amounts and numbers of buffers. “Our simplest processes are the most elegant,” says Dr. Jeffrey Deetz, Wyeth’s senior director of drug substance development, “but they take the most time to develop while maintaining the usual goals of purity, product profile and quality.”
On the development side, Wyeth has adopted a platform approach, currently a two-column process. Engineers use a 96-well, plate-based, high-throughput screening method to optimize washes, salt concentrations, pH, buffer excipients and other performance-enhancing parameters for the two columns.
“If we can do a quick survey and not hold up the critical evaluation of biopharmaceutical candidates, then we can tailor at least some aspects of the purification train to give a better product profile for early evaluations,” says Deetz. “At the same time we don’t want to over-invest in all these candidates because so many are coming through the pipeline.”Orthogonal operations
Demonstrating viral clearance will always be part of mammalian cell-based downstream processing. The trend from animal-derived media components to completely defined media will reduce the viral clearance validation burden somewhat, since processors need only worry about infectious agents from cultured cells and not from media components. However, the virus-generating potential from protein-producing cells will exist as long as such cells are used.
Dedicated viral clearance filtration is usually deployed as far downstream as possible due to the membranes’ tendency to foul and clog. “Filter fouling can seriously affect process economics,” says Dr. Jeff Carter, consulting product manager at Millipore Corp. (Billerica, Mass.). In practice, unit operations provide multiple, orthogonal operations to achieve clearances on the order of 12 to 18 log. Virus-clearing capability is built into filtration and chromatography. Additional filtration or inactivation steps are added as needed to reduce virus levels to FDA/EMEA standards.